Dimensional Fund Advisors LP Trims Stake in Natus Medical Inc (BABY)

Dimensional Fund Advisors LP lowered its holdings in shares of Natus Medical Inc (NASDAQ:BABY) by 0.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,613,189 shares of the medical equipment provider’s stock after selling 6,148 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Natus Medical were worth $54,284,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BABY. Teacher Retirement System of Texas bought a new position in shares of Natus Medical during the 4th quarter valued at approximately $433,000. Swiss National Bank grew its stake in shares of Natus Medical by 4.4% during the 4th quarter. Swiss National Bank now owns 56,500 shares of the medical equipment provider’s stock valued at $2,158,000 after acquiring an additional 2,400 shares during the period. Pinebridge Investments L.P. grew its stake in shares of Natus Medical by 267.1% during the 4th quarter. Pinebridge Investments L.P. now owns 15,103 shares of the medical equipment provider’s stock valued at $577,000 after acquiring an additional 10,989 shares during the period. Rhumbline Advisers grew its stake in shares of Natus Medical by 11.9% during the 4th quarter. Rhumbline Advisers now owns 75,020 shares of the medical equipment provider’s stock valued at $2,866,000 after acquiring an additional 7,955 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Natus Medical during the 4th quarter valued at approximately $10,445,000. 89.20% of the stock is owned by hedge funds and other institutional investors.

In other Natus Medical news, Director William M. Moore sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 16th. The stock was sold at an average price of $35.91, for a total value of $287,280.00. Following the completion of the transaction, the director now directly owns 30,410 shares in the company, valued at approximately $1,092,023.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James B. Hawkins sold 160,000 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $33.47, for a total value of $5,355,200.00. Following the completion of the transaction, the insider now owns 686,757 shares of the company’s stock, valued at $22,985,756.79. The disclosure for this sale can be found here. Insiders sold a total of 183,358 shares of company stock valued at $6,154,209 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Natus Medical opened at $36.75 on Monday, Marketbeat.com reports. Natus Medical Inc has a 1-year low of $28.00 and a 1-year high of $43.60. The company has a quick ratio of 2.28, a current ratio of 3.06 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 25.34 and a beta of 0.49.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $0.24 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.24. Natus Medical had a positive return on equity of 10.96% and a negative net margin of 4.71%. The business had revenue of $128.60 million during the quarter, compared to the consensus estimate of $125.91 million. During the same period in the prior year, the company posted $0.30 EPS. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. sell-side analysts expect that Natus Medical Inc will post 1.62 EPS for the current fiscal year.

A number of brokerages recently issued reports on BABY. BidaskClub upgraded Natus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, April 21st. Zacks Investment Research upgraded Natus Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 10th. ValuEngine downgraded Natus Medical from a “hold” rating to a “sell” rating in a research note on Thursday, May 3rd. Finally, Roth Capital set a $39.00 price objective on Natus Medical and gave the company a “buy” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $44.33.

Natus Medical Company Profile

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply